INOMAX

Peak

nitric oxide

NDAINHALATIONGASPriority Review

Approved

Dec 1999

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide selectively dilates the pulmonary vasculature, and because of efficient scavenging by hemoglobin, has minimal effect on the…

Pharmacologic Class:

Vasodilator

Indications (6)

oxygenation reduce the need for extracorporeal membrane oxygenation in term near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support other appropriate agents hypertension

Clinical Trials (5)

NCT07438951N/ANot Yet Recruiting

A Study on the Efficacy and Safety of a Nitric Oxide Generating Dressing in the Treatment of Diabetes Related Foot Ulcers.

Started Jul 2026

102 enrolled

Diabetic Foot Ulcers (DFUs)

NCT07099144N/ARecruiting

Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertension

Started Dec 2024

120 enrolled

Pulmonary HypertensionHypoxic Respiratory Failure

NCT05992519N/ACompleted

Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma

Started Nov 2022

123 enrolled

AsthmaAsthma in ChildrenDiagnosis+1 more

NCT05052229Phase 1Recruiting

Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).

Started Apr 2022

40 enrolled

Idiopathic Pulmonary Fibrosis

NCT04800692Phase 1Recruiting

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

Started Jun 2021

10 enrolled